ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0566

How Early Is Early? Unveiling Time to Diagnosis Since Symptom Onset and Its Determinants in Patients Suspected of Early Axial Spondyloarthritis: Data from the SPondyloArthritis Caught Early (SPACE) Cohort

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0501

How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0028

Human Meniscus Histopathological and Transcriptomic Changes at Early and Advanced Stages of Knee Osteoarthritis

Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0243

Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID-19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment

Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0152

Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0675

Hydroxychloroquine Induced Cardiomyopathy: A Biopsy Proven Case Series

SLE – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0674

Hydroxychloroquine Screening Adherence: Insights from Highmark Claims Data

SLE – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0660

Hydroxychloroquine Users at Lower Risk of Kidney Function Decline in Lupus Nephritis

SLE – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0288

Hypersensitivity Pneumonitis with Autoimmune Features: A New Entity?

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0310

I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0284

Identification of Calcium Pyrophosphate Deposition Using Ultrasonography in Patients with a Suspected Diagnosis of Seronegative Rheumatoid Arthritis

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0383

Identification of Protein Biomarkers in Tear Fluid of Children with Uveitis That Distinguishes the Ocular Inflammatory State

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0705

Identification of Risk Factors for Incident Cardiomyopathy in Patients with Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0353

Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach

Patient Education/Community Programs Poster – ARP

10:30AM-12:30PM: Abstract Number: 0328

IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].